WO2011070252A1 - Azabicyclo[3.2.0]hept-6-yl derivatives as antagonists of histamine h3 receptor - Google Patents

Abstract

The invention relates to compounds of formula (I), where ALK is an alkylene chain, and W is a grouping (AA) or (BB), where R and R' are as defined in the description. Said compounds are used as antagonists of central histamine H3 receptors.

Description

 AZABICYCLO [3.2.0] HEPT-6-YLE DERIVATIVES AS ANTAGONISTS

 HISTAMINERGIC RECEPTORS TYPE H3

The present invention relates to novel azabicyclo [3.2.0] hept-6-yl derivatives, process for their preparation and pharmaceutical compositions containing them.

The compounds of the present invention are particularly valuable from a pharmacological point of view for their interaction with central histaminergic systems in vivo.

The aging of the population, as a result of the increase in life expectancy at birth, has also led to a large increase in the incidence of age-related neuropathologies, including Alzheimer's disease. The main clinical manifestations of cerebral aging and especially age-related neuropathologies are deficits in memory and cognitive functions that can lead to dementia. At the level of the central nervous system, neuropharmacological studies have shown that histamine-mediated histamine systems play a role of neurotransmitter or neuromodulator in physiological or physiopathological situations (Pell and Green, Annu Rev. Neurosci., 1986, 9, 209-254 Schwartz et al., Physiol Rev., 1991, 71, 1-51). Thus, it has been shown that rhistamine is involved in various physiological and behavioral processes such as thermoregulation, neuroendocrine regulation, nociception, circadian rhythm, cataleptic states, motor skills, aggression, eating behavior, learning and memorization, as well as synaptic plasticity (Hass et al., Histaminergic Neurons: Morphology and Function, Boca Raton, FL: CRC Press, 1991, pp. 196-208, Brown et al., Prog Neurobiology, 2001, 63, 637-672, Smith et al., Neuroimmunomodulation 2007, 14, pp. 317-325). Studies in animals have shown that the increase in endogenous extra-synaptic levels of histamine can promote states of alertness, learning and memory processes and regulate food intake (Brown et al. Prog Neurobiol., 2000, 63, 637-672, Passani et al., Neurosci, Biobehav, Rev., 2000, 24, 107-113). Consequently, the potential therapeutic indications for compounds capable of increasing turnover or the release of histamine at the central level are the treatment of cognitive deficits associated with cerebral aging, acute and chronic neurodegenerative diseases, schizophrenia and that treatment of mood disorders, Tourette's syndrome (Gulhan Ercan-Sencicek et al., New England Journal of Medicine, May 20, 2010, 1901-1908), schizophrenia, sleep disorders and sleep rhythm -sleep, hyperactivity syndrome with attention deficit. In addition, studies have shown that a histamine injection into the central hypothalamic nuclei involved in the regulation of satiety attenuates the diet in the rat. In addition, hypofunctioning of histaminergic transmission has been demonstrated in genetically obese rats (Machidori et al., Brain Research, 1992, 590, 180-186). Accordingly, eating disorders and obesity are also potential therapeutic indications for the compounds of the present invention.

The present invention relates to novel azabicyclic derivatives which are distinguished from the compounds exemplified in WO2005 / 089747 by the presence of a 6-azabicyclo [3.2.0] heptane ring.

At the neurological level, these new compounds open the way not only to new treatments for cognitive disorders related to cerebral aging, neurodegenerative diseases or head trauma, but also to the treatment of psycho-behavioral disorders associated with these pathologies such as sleep disorders, apathy and / or depressive states. Moreover, the pharmacological profile of the compounds of the invention also makes it possible to envisage new treatments in the psychiatric field, for Tourette's syndrome, schizophrenia, mood or sleep disorders, for example. The present invention relates more particularly to the compounds of formula (I):

dans laquelle :

in which :

♦ ALK represents an alkylene chain,

♦ W represents a group R

where R and R 'represent, independently of one another, a hydrogen atom or a linear or branched (C ₁ -C ₆ ) alkyl group optionally substituted with one or more groups chosen from halogen, hydroxy and alkoxy, it being understood that :

 the term alkylene denotes a bivalent radical, linear or branched, containing from 2 to 6 carbon atoms,

 the term alkoxy denotes an alkyl-oxy group whose linear or branched alkyl chain contains from 1 to 6 carbon atoms, their enantiomers and diastereoisomers, and also their addition salts with a pharmaceutically acceptable acid or base.

Among the pharmaceutically acceptable acids, mention may be made, without limitation, of hydrochloric, hydrobromic, sulfuric, phosphonic, acetic, trifluoroacetic, lactic, pyruvic, malonic, succinic, glutanic, fumaric, tartaric, maleic, citric, ascorbic, oxalic and methane acids. sulfonic, camphoric, etc. Among the pharmaceutically acceptable bases, mention may be made, without limitation, of sodium hydroxide, potassium hydroxide, triethylamine, tertbutylamine, and the like.

The preferred compounds of formula (I) are those for which the group W is located in the para position. Preferably, AL represents a linear divalent radical containing from 2 to 6 carbon atoms such as, for example, the ethylene or propylene group, and more preferably still a propylene group.

A particular aspect of the invention relates to the compounds of formula (I) for which W represents the group --N-R-.

 gold'

Another particular aspect of the invention relates to the compounds of formula (I) for which W represents the group N- ^ - R.

 R 'o

Advantageously, R and R 'represent, independently of one another, the hydrogen atom, the methyl group or the ethyl group, these groups being optionally substituted by a methoxy. More particularly, W represents the group -CO-NH-CH 3, -CO-N (CH ₃ ) ₂ , -CO-NH ₂ , -CO-N (CH ₂ CH ₃ ) ₂ , -NH-CO-CH ₃ , -N (CH ₃ ) -CO-CH ₃ or -NH-CO-CH ₂ -OCH ₃ .

Even more particularly, the invention relates to the compounds of formula (I) which are: 4- [3- (cw-6-azabicyclo [3.2.0] hept-6-yl) propoxy] benzamide,

 N- (4- {3- (C 1-6 -azabicyclo [3.2.0] hept-6-yl) propoxy} phenyl) acetamide,

 4- {3- (c 5- 6 -azabicyclo [3.2.0] hept-6-yl) propoxy} -N-dimethylbenzamide,

4- {3- (c / ^5, -6-azabicyclo [3.2.0] hept-6-yl) propoxy} -N V-diethylbenzamide, N- (4- {3- (cw-6-azabicyclo [ 3.2.0] hept-6-yl) propoxy} phenyl) -N-methylacetamide, and their enantiomers and addition salts thereof with a pharmaceutically acceptable acid or base. Among the addition salts with a pharmaceutically acceptable acid, the hydrochloride, oxalate and citrate are more particularly preferred.

The invention also extends to the process for preparing the compounds of formula (I), characterized in that the compound of formula (II) used is the starting material:

dans laquelle W est tel que défini dans la formule (I), composé de formule (II) sur lequel on condense en milieu basique le composé de formule

in which W is as defined in formula (I), compound of formula (II) on which the compound of formula

(III):

Br ALK-Cl (ffl) in which ALK is as defined in formula (I), to obtain the compound of formula (IV):

dans laquelle W et ALK sont tels que définis précédemment,

in which W and ALK are as defined above,

on which the compound of formula (V) is condensed:

pour conduire au composé de formule (I) tel que défini précédemment :

qui peut être purifié selon une technique classique de séparation, que l'on transforme, si on le souhaite, en ses sels d'addition à un acide ou à une base pharmaceutiquement acceptable et dont on sépare éventuellement les isomères optiques selon une technique classique de séparation.

to yield the compound of formula (I) as defined above:

which can be purified according to a conventional separation technique, which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base and from which the optical isomers are optionally separated according to a conventional technique of separation.

The compounds of formulas (II), (III) and (V) are either commercially available or accessible to those skilled in the art by conventional cliimic reactions and described in the literature.

Alternatively, the compounds of formula (VI):

dans lesquels le groupement ALK est tel que défini précédemment, peuvent être utilisés en tant qu'intermédiaires de synthèse des composés de formule (I/a), cas particuliers des composés de formule (I) pour lesquels W représente un groupement -CONRR', par couplage avec une aminé de formule NHRR', où R et R' ont la même signification que dans la formule (I). De même, les composés de formule (VII) :

in which the ALK group is as defined above, can be used as synthetic intermediates for the compounds of formula (I / a), in particular cases of the compounds of formula (I) for which W represents a group -CONRR ', by coupling with an amine of formula NHRR ', where R and R' have the same meaning as in formula (I). Similarly, the compounds of formula (VII):

dans lesquels le groupement ALK est tel que défini précédemment, peuvent être utilisés en tant qu'intermédiaires de synthèse des composés de formule (I/a), cas particuliers des composés de formule (I) pour lesquels W représente un groupement -CONRR', par couplage avec une aminé de formule NHRR', où R et R' ont la même signification que dans la formule (I).

in which the ALK group is as defined above, can be used as synthetic intermediates for the compounds of formula (I / a), in particular cases of the compounds of formula (I) for which W represents a group -CONRR ', by coupling with an amine of formula NHRR ', where R and R' have the same meaning as in formula (I).

In addition, the compounds of formula (I / a), particular cases of the compounds of formula (I) for which W represents a group -CONRR ', can also be obtained by amine condensation NHRR', where R and R 'have the same meaning as in formula (I), using the compounds of formula (VIII):

dans lesquels le groupement ALK est tel que défini précédemment et R" représente un groupement alkyle (CrC₆) linéaire ou ramifié ou un groupement benzyle, les composés de formule (VIII) étant préparés via l'acide carboxylique (VI) ou le chlorure d'acyle (VII) correspondant présentés précédemment :

in which the ALK group is as defined above and R "represents a linear or branched (C ₁ -C ₆ ) alkyl group or a benzyl group, the compounds of formula (VIII) being prepared via the carboxylic acid (VI) or the dichloride corresponding acyl (VII) presented above:

dans lesquels le groupement ALK est tel que défini précédemment. Finally, it is also possible to obtain the compounds of formula (I / a) by hydrolyzing compounds of formula (IX):

in which the grouping ALK is as defined previously.

At the neurological level, the compounds according to the invention may be useful in the treatment of cognitive disorders related to cerebral aging or to neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Pick's disease, body dementia. Lewy, frontal and subcortical dementia, frontotemporal dementia, vascular dementia, Huntington's disease, multiple sclerosis, in new treatments for cognitive disorders related to head trauma, but also in the treatment of psycho-behavioral disorders associated with these pathologies such as sleep disorders, apathy and anxio-depressive states. Sleep disorders associated with Alzheimer's disease and Parkinson's disease, such as daytime hypersomnolence, are particularly targeted.

At the psychiatric level, these compounds may be useful in the treatment of mood disorders, and more particularly the treatment of anxio-depressive states, Tourette's syndrome, schizophrenia and cognitive disorders associated with it, pain , as well as in the treatment of sleep disorders, sleep-wake rhythm and Attention Deficit Hyperactivity Syndrome (ADHD). Sleep disorders include narcolepsy and sleep apnea. Sleep disorders such as hypersomnias occurring during obstructive sleep apnea syndrome or attention deficit hyperactivity syndrome, as well as daytime sleepiness are also targeted.

The present invention also relates to pharmaceutical compositions containing a compound of formula (I) in combination with one or more pharmaceutically acceptable excipients. - Si - In the pharmaceutical compositions according to the invention, the mass fraction of active ingredient (mass of the active ingredient on the total mass of the composition) is between 1 and 50%.

Among the pharmaceutical compositions according to the invention, mention may be made, more particularly, of those which are suitable for oral, parenteral, nasal, percutaneous, rectal, perlingual, ocular or respiratory administration and in particular simple or coated tablets, sublingual tablets. , sachets, packets, capsules, glossettes, lozenges, suppositories, creams, ointments, dermal gels, and oral or injectable ampoules. The dosage varies according to the sex, age and weight of the patient, the route of administration, the nature of the therapeutic indication, or possibly associated treatments and ranges between 0.05 mg and 500 mg per 24 hours. for treatment in 1 to 3 doses per day.

The combination of a compound of formula (I) with an acetylcholmesterase inhibitor is also an integral part of the invention, and more particularly the combination of a compound of formula (I) with donepezil, rivastigmine or galantamine. Associations of this type can be used in the treatment of cognitive disorders associated with Alzheimer 's disease.

The following examples illustrate the invention and do not limit it in any way. The structures of the compounds, described in the examples, were determined according to the usual spectrophotometric techniques (infrared, RJVIN, mass spectrometry, etc.).

By way of information, the compounds below correspond to racemates of cis configuration. In other words, these compounds correspond to racemic mixtures of skeletons (Li 2, 5i) -6-azabicyclo [3.2.0] hept-6-yl and backbones (1S, 5S) -6-azabicyclo [3.2 .0] hept-6-yl.

As mentioned in the examples below, the racemic mixtures can be separated to obtain the pure enantiomers by chiral separation techniques on HPLC column, for example, type CHIRALCEL OF, CHIRALPACK AS-H or CHIRALPACK AD-H.

Example 1, synthetic route A: 4- [3- (c -6-azabicyclo [3.2.0] hept-6-yl) -propoxy]

 Benzamide Step 1: 4- (3-Chloropropoxy) benzamide

 A mixture consisting of 0.004 moles of 4-hydroxybenzamide, 0.004 moles of 1-bromo-3-chloropropane and 0.006 moles of cesium carbonate in 10 ml of acetonitrile is refluxed for 5 hours.

Step 2: 4- [3- (cis-6-azabicyclo [3.2.0] hept-6-yl) propoxy] benzamide

In the reaction medium of stage 1 at room temperature are added 0.004 mol of the latter ^{'5-6-azabicyclo} [3.2.0] heptane, whose synthesis is described in the publication J. Chem.

Soc. Perkin Trans. 1979, pp. 1770-1773, and 0.002 moles of sodium iodide. The refluxing heating is then resumed for 16 hours. The precipitate is filtered and rinsed with acetonitrile. The filtrate is concentrated to dryness. The residue is taken up in dichloromethane. This solution is extracted with sodium hydroxide and then with water, before being dried over magnesium sulphate and concentrated to dryness. The residue is purified by preparative chromatography technique on Lichroprep RP-18 phase.

Elemental microanalysis:

 % c% H% N

 Calculated 70.04 8.08 10.21

 Found 70.06 8.11 10.00

Example 1, Route B: 4- [3- (cw-6-azabicyclo [3.2.0] hept-6-yl) propoxy] benzamide

Step 1: 4- {3- (cis-6-azabicyclo [3.2.0] hept-6-yl) propoxy} benzonitrile

The experimental procedure is identical to that of Example 1, synthetic route A, replacing in Step 1 the 4-hydroxybenzamide by 4-hydroxybenzonitrile. Step 2: 4- [3- (cis-6-azabicyclo [3.2.0] hept-6-yl) propoxy] benzamide

The compound obtained in the preceding stage (2.2 g) is dissolved in 90 ml of ethanol and heated under reflux in the presence of 5.1 g of KOH for 18 hours. The medium is poured into 90 ml of water and then concentrated to half volume under vacuum. The solid obtained is filtered, rinsed with isopropyl ether and dried.

Elemental microanalysis:

 % C% H% N

 Calculated 70.04 8.08 10.21

 Found 69.64 8.01 10.17 Example 1, Route C: 4- [3- (c -6-azabicyclo [3.2.0] hept-6-yl) propoxy] benzamide

Step 1: Methyl 4- {3- (cis-6-azabicyclo [3.2.0] hept-6-yl) propoxy} benzoate

 The experimental procedure is identical to that of Example 1, synthetic route A, replacing in Stage 1 the 4-hydroxybenzamide with methyl 4-hydroxybenzoate.

Step 2: 4- {3- (cis-6-azabicyclo [3.2.0] hept-6-yl) propoxy} benzoic acid

A mixture of 3.5 g of the Step 1 compound, 12.7 ml of 2 N sodium hydroxide and 8 ml of methanol is refluxed for one hour. 12.7 ml of 2N HCl are added to the reaction medium cooled in an ice bath. The precipitate is washed with water and dried under vacuum.

Step 3: 4- {3- (cis-6-azabicyclo [3.2.0] hept-6-yl) propoxy} benzoyl chloride

 hydrochloride

A mixture of 1.8 g of product described in Step 2 and 20 ml of thionyl chloride is refluxed for 2 hours. The reaction medium is concentrated under vacuum, coevaporated twice with toluene. The solid residue is homogenized in ethyl ether, filtered and dried under vacuum. Step 4: 4- [3- (c-6-azabicyclo [3.2.0] hept-6-yl) propoxy] benzamide

In a solution of 1 g of the product described in Step 3 in dichloromethane at 0 ° C., 4 ml of 2N ammoniacal methanol are added dropwise. The mixture is then stirred for 1 hour at room temperature, washed with sodium hydroxide solution. 2 N, then water. The organic phase is dried over magnesium sulfate and concentrated. The solid obtained is filtered, rinsed with isopropyl ether and dried.

Elemental microanalysis:

 % C% H% N

 Calculated 70.04 8.08 10.21

Found 69.90 8.05 10.19

Example 2: 4- {2- (c -6-azabicyclo [3.2.0] hept-6-yl) ethoxy} benzamide

The experimental procedure is identical to that of Example 1, synthesis route A, replacing in Step 1 1-bromo-3-chloropropane with 1-bromo-2-chloroethane.

Elemental microanalysis:

 % C% H% N

 Calculated 69.21 7, 74 10, 76

 Found 68.99 7, 71 10.28

Example 3: N- (4- {3- (α-6-azabicyclo [3.2.0] hept-6-yl) propoxy} phenyl) acetamide oxalate The experimental procedure is identical to that of Example 1, route Synthesis A, replacing in Step 1 the 4-hydroxybenzamide with N- (4-hydroxyphenyl) acetamide. 0.36 g of oxalic acid is then added to 0.40 g of the compound thus obtained in 6 ml of ethanol. The product obtained is filtered, rinsed with ethyl ether and then dried under vacuum. Elemental microanalvse:

 % C% H% N

Calculated 60.31 6.92 7.40

 Found 60.47 6, 71 7.26 Example 4: N- (4- {2- (cis-6-azabicyclo [3.2.0] hept-6-yl) ethoxy} phenyl) oxalate

 acetamide

The experimental procedure is identical to that of Example 2, replacing in Stage 1 the 4-hydroxybenzamide by V- (4-hydroxyphenyl) acetamide. 0.36 g of oxalic acid is then added to 0.38 g of the compound thus obtained in 6 ml of ethanol. The product obtained is filtered, rinsed with ethyl ether and then dried under vacuum.

Elemental microanalvse:

 % C% H

Calculated 59.33 6.64

 Found 58.89 6.30 Example 5: 4- {3- (cis-6-azabicyclo [3.2.0] hept-6-yl) propoxy} -N, 2V-dimethylbenzamide hydrochloride

The experimental procedure is identical to that of Example 1, synthetic route A, replacing in Step 1 the 4-hydroxybenzamide with 4-hydroxy-N, N-dimethylbenzamide. The product thus obtained is dissolved in 10 ml of ethanol to which 2 ml of 2N hydrochloric ether are added. The crystallized product is filtered, rinsed with ethanol and dried under vacuum.

Elemental microanalvse:

 % C% H% N% Cl-

Calculated 63.80 8.03 8.27 10.46

Found 63.22 7.60 7.94 10.42 Example 6: 4- {3- (cK-6-azabicyclo [3.2.0] hept-6-yl) propoxy} -N-diethylbenzamide oxalate

The experimental procedure is identical to that of Example 3, replacing in Stage 1 N- (4-hydroxyphenyl) acetamide with 4-hydroxy-N, N-diethylbenzamide. Elemental microanalysis:

 % C% H% N

Calculated 62.84 7.67 6.66

 Found 61.97 7.51 6, 74

Example 7 4- {3- (cis-6-azabicyclo [3.2.0] hept-6-yl) propoxy} -N-methylbenzamide hydrochloride

The experimental procedure is identical to that of Example 5, replacing in Stage 1 4-hydroxy-N, N-dimethylbenzamide with 4-hydroxy-N-methylbenzamide.

Elemental microanalysis:

 % C% H% N% Cl- Calculated 62.86 7.66 10.91

 Found 62.58 7.65 8.65 10.87

Example 8: N- (4- {3- (c "-6-Azabicyclo [3.2.0] hept-6-yl) propoxy Hydrochloride}

 phenyl) -N-methylacetamide

The experimental procedure is identical to that of Example 5, replacing in Stage 1 4-hydroxy-N, N-dimethylbenzainide with N- (4-hydroxyphenyl) -N-methylacetamide.

Elemental microanalysis:

 % C% H% N% Cl-

Calculated 63.80 8.03 8.27 10.46

Found 63.47 7.81 8.00 11.09 Example 8a: ^L (4- {3- (cis-6-azabicyclo [3.2.0] hept-6-yl) propoxy} phenyl) -N-methylacetamide hydrochloride (enantiomer 1)

The enantiomer 1 was obtained by preparative separation on a chiral column CHIRALCEL OF 60X (600mm 20μπι)

Example 8b: A '- (4- {3- (c) -6-azabicyclo [3.2.0] hept-6-yl) propoxy} phenyl) -N-methylacetamide hydrochloride (enantiomer 2)

Enantiomer 2 was obtained by preparative separation on chiral column CHIRALCEL OF 60X (600mm 20μηι)

Example 9; V- (4- {3- (cis-6-azabicyclo [3.2.0] hept-6-yl) propoxy hydrochloride}

 phenyl) -2-methoxy-acetamide

The experimental procedure is identical to that of Example 5, replacing in Step 1 4-hydroxy-N-dimethylbenzamide by N- (4-hydroxyphenyl) -2-methoxyacetamide.

Elemental microanalysis (for 1.2 HCl)

 % C% H% N% Cl-

Calculated 59, 70 7.57 7, 74 11, 75

Found 58.19 7.83 6.94 12.07

PHARMACOLOGICAL STUDY

EXAMPLE A Brain Assays of N ^T- Methylhistamine in the NMRI Mouse

This study carried out according to the method of Taylor et al. (Biochem Pharm., 1992, 44, 1261-1267), aims to evaluate the ex vivo activity of the compounds of the present invention as H ₃ central riistaminergic receptor antagonists. This activity is revealed by the measurement, after oral treatment of the compounds under study, of the central levels of N ^T- methylhistamine, main metabolite of histamine. An increase in brain levels of N ^T- methylhistamine leads to an increase in histamine turnover by blocking H ₃ central histaminergic receptors. NMRI mice (18-20 g) are orally treated with the compounds of the present invention or their vehicle (20 ml / kg). One hour after the pharmacological treatment, the animals are sacrificed, the brains are removed, frozen in liquid nitrogen, weighed and homogenized in 0.1 N HClO4 at 4 ° C. The homogenates are centrifuged (15,000 g, 17 minutes, 4 ° C). The supernatants are recovered and aliquoted. The aliquots are frozen in liquid nitrogen and stored at -80 ° C until analyzed.

The determination of the brain levels of N ^T- methylhistamine is carried out by capillary electrophoresis. The tissue levels of N ^T -methyl-malamine are expressed in g / g of fresh brain. The comparison of the brain levels of N ^T- methylhistamine between the vehicle-treated animals (controls) and the animals treated with the compounds of the present invention is carried out by a one-way analysis of variance followed, if necessary, by a complementary analysis (test Dunnett).

The results show that the compounds of the present invention are capable, at a dose of 3 mg / kg PO, of significantly increasing the endogenous brain concentrations of N ^T- methylhistamine by more than 80%. By way of example, the compounds of Examples 1, 3, 6, 8 and 5, administered at 3 mg / kg PO, increase the endogenous brain concentrations of N ^T- methylhistamine, respectively of:

 Compound of Example 1: + 125%

 Composed of Example 3: + 111%

 Composed of Example 6: + 86%

 Compound of Example 8: + 87%

 Composed of Example 5: + 81%

This result indicates that the compounds of the present invention are potent H ₃ central histaminergic receptor antagonists.

EXAMPLE B Affinity on Murine H ₃ Receptors

The objective is to measure affinity of compounds of the present invention for type murine histamine H ₃ receptor transfected into CHO cells.

The compounds are incubated at different concentrations in the presence of transfected CHO cells, a radiolabelled ligand, iodoproxifan, spécifique receptor-specific and scintillating beads for 24 hours at room temperature.

At the end of the incubation, the displacement of the specific binding of the ligand by the test compounds is measured, and the affinity constants of these compounds for the mouse H ₃ receptors are determined.

The results show that the compounds of the invention have a very good affinity (Ki <40 nM) for H ₃ type histaminergic receptors. For exemple :

 Compound of Example 6: Ki = 21 nM

 Compound of Example 8: Ki = 14 nM

Compound of Example 5: Ki = 35 nM EXAMPLE C Pharmaceutical Compositions

Preparation formula for 1000 tablets dosed at 100 mg:

 Compound of Example 1 100 g

Hydroxypropylcellulose 20 g

Polyvinylpyrrolidone 20 g Wheat starch 150 g

Lactose 900 g

Magnesium stearate 30 g

Claims

1. Compounds of formula (I):

in which : ♦ ALK represents an alkylene chain, ♦ W represents a group N-- R or ^ - N-R  R 'o O R' where R and R 'represent, independently of one another, a hydrogen atom or a linear or branched (C ₁ -C 4) alkyl group optionally substituted with one or more groups chosen from halogen, hydroxy and alkoxy, being heard that:  the term alkylene denotes a bivalent radical, linear or branched, containing from 2 to 6 carbon atoms,  the term alkoxy denotes an alkyl-oxy group whose linear or branched alkyl chain contains from 1 to 6 carbon atoms, their enantiomers and diastereoisomers, and also their addition salts with a pharmaceutically acceptable acid or base. 2. Compounds of formula (I) according to claim 1 for which the group W is located in the para position. 3. Compounds of formula (I) according to claim 1 wherein ALK represents an ethylene or propylene group, their enantiomers and diastereoisomers and addition salts with a pharmaceutically acceptable acid or base. 4. Compounds of formula (I) according to claim 1 wherein ALK represents a propylene group, their enantiomers and diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid or base. 5. Compounds of formula (I) according to claim 1 wherein W represents a group - R, their enantiomers and diastereoisomers and their salts o R ' addition to a pharmaceutically acceptable acid or base. 6. Compounds of formula (I) according to claim 1 wherein W represents a group N- ^ - R, their enantiomers and diastereoisomers and their salts  R 'o addition to a pharmaceutically acceptable acid or base. 7. Compounds of formula (I) according to claim 1 wherein R and R 'represent, independently of one another, a hydrogen atom, a methyl group or an ethyl group, these groups being optionally substituted by a methoxy, their enantiomers and diastereoisomers as well as their addition salts with a pharmaceutically acceptable acid or base. 8. Compounds of formula (I) according to claim 1 wherein W represents a group -CO-NH ₂ , -CO-NH-CH ₃ , -CO-N (CH ₃ ) ₂ , -CO-N (CH ₂ CH ₃ ) ₂ -NH-CO-CH ₃ , -N (CH ₃ ) -CO-CH ₃ or -NH-CO-CH ₂ -OCH ₃ , their enantiomers and diastereoisomers as well as their addition salts with an acid or to a pharmaceutically acceptable base. 9. Compounds of formula (I) according to claim 1 which are: 4- [3- (C5 ^, 6-azabicyclo [3.2.0] hept-6-yl) propoxy] benzamide, N- (4- {3- (C 1-6 -azabicyclo [3.2.0] hept-6-yl) propoxy} phenyl) acetamide, 4- {3 - (cw-6-azabicyclo [3.2.0] hept-6-yl) propoxy} -N, N-dimethylbenzamide, 4- {3 - (cw-6-azabicyclo [3.2.0] hept-6-yl) propoxy} -N-diethylbenzamide, N- (4- {3- (cw-6-azabicyclo [3.2.0] hept-6-yl) propoxy} phenyl) -N-methylacetamide, and their enantiomers and their addition salts with an acid or a pharmaceutically acceptable base. 10. Process for the preparation of the compounds of formula (I) according to claim 1, characterized in that the compound of formula (II) used is the starting material:

in which W is as defined in claim 1, compound of formula (II) on which the compound of formula (III): Br ALK-Cl (ΠΙ) in which ALK is as defined in formula (I), to obtain the compound of formula (IV):

in which W and ALK are as defined above, on which the compound of formula (V) is condensed:

to yield the compound of formula (I) as defined above:

which can be purified according to a conventional separation technique, which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base and from which the optical isomers are optionally separated according to a conventional technique of separation. 11. Compounds of formula (VI) below:

in which the ALK group is as defined in claim 1, useful as synthesis intermediates for the compounds of formula (I / a), in particular cases of the compounds of formula (I) according to claim 1 for which W represents a group -CONRR ', since W, R and R' are as defined in claim 1. 12. Compounds of formula (VII) below:

in which the ALK group is as defined in claim 1, useful as synthesis intermediates for the compounds of formula (Va), in particular cases of the compounds of formula (I) according to claim 1 wherein W represents a group -CONRR ', since W, R and R' are such as defined in claim 1. 13. Compounds of formula (VIII) below:

wherein the ALK group is as defined in claim 1 and R "is alkyl (Ci-C ₆₎ linear or branched alkyl or a benzyl group, useful as synthesis intermediates for the compounds of formula (I / a), in particular cases of the compounds of formula (I) according to claim 1 for which W represents a group -CONRR ', since W, R and R' are as defined in claim 1. 14. Compounds of formula (IX) below:

in which the ALK group is as defined in claim 1, useful as synthesis intermediates for the compounds of formula (I / a), in particular cases of the compounds of formula (I) according to claim 1 for which W represents a group -CONRR ', since W, R and R' are as defined in claim 1. 15. Pharmaceutical compositions containing as active ingredient a compound of formula (I) according to any one of claims 1 to 9, or one of its addition salts with a pharmaceutically acceptable acid or base, in combination with one or more pharmaceutically acceptable excipients. 16. Pharmaceutical compositions according to claim 15 for their use in the treatment of cognitive and psycho-behavioral disorders related to cerebral aging, neurodegenerative diseases or cranial trauma. 17. Pharmaceutical compositions according to claim 16 for their use in the treatment of cognitive and psycho-behavioral disorders associated with Alzheimer's disease, Parkinson's disease, Pick's disease, Lewy body dementia, frontal and subacute dementias. cortical, frontotemporal dementia, vascular dementia, Huntington's disease, and multiple sclerosis. 18. Pharmaceutical compositions according to claim 16 for their use in the treatment of psycho-behavioral disorders such as sleep disorders, apathy and anxio-depressive states. 19. Pharmaceutical compositions according to claim 18 for their use in the treatment of sleep disorders associated with Alzheimer's disease and Parkinson's disease. 20. Pharmaceutical compositions according to claim 15 for their use in the treatment of mood disorders, anxiety-depressive states, Tourette's syndrome, schizophrenia and cognitive disorders associated with it, pain, as well as in the treatment of sleep disorders, sleep-wake rhythm and hyperactivity syndrome with attentional deficits. 21. Pharmaceutical compositions according to claim 20 for use in the treatment of sleep disorders such as narcolepsy, hypersomnias occurring during obstructive sleep apnea syndrome or attention deficit hyperactivity syndrome, as well as daytime sleepiness. . 22. Combination of a compound of formula (I) according to any one of claims 1 to 9 with an acetylcholinesterase inhibitor. 23. Combination of a compound of formula (I) according to any one of claims 1 to 9 with donepezil, galantamine or rivastigmine. 24. Association according to claim 22 or 23 for its use in the treatment of cognitive disorders associated with Alzheimer's disease.